Current Management Strategy for Penile Cancer and Future Directions
Purpose of Review The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy. Recent Findings Organ preservation (surgical or incorporating radiati...
Gespeichert in:
| Veröffentlicht in: | Current oncology reports 2017-08, Vol.19 (8), p.54-54, Article 54 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 54 |
|---|---|
| container_issue | 8 |
| container_start_page | 54 |
| container_title | Current oncology reports |
| container_volume | 19 |
| creator | Dorff, Tanya B. Ballas, Leslie K. Schuckman, Anne K. |
| description | Purpose of Review
The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy.
Recent Findings
Organ preservation (surgical or incorporating radiation) and reconstructive techniques are important considerations for quality of life in penile cancer survivors. Although local recurrence may be higher with organ preservation, salvage therapy appears successful. Inguinal and pelvic node management requires multidisciplinary care, including chemotherapy; optimal use of radiation has not been fully defined. Advanced in understanding the biology of penile cancer, particularly with regard to epidermal growth factor receptor (EGFR) and HPV status, have led to clinical trials of targeted and immune therapy for patients with refractory disease.
Summary
Refinements in the management of penile cancer are occurring, though level 1 evidence remains scarce. Referral to specialized centers will facilitate successful completion of clinical trials to advance standard care in this disease. |
| doi_str_mv | 10.1007/s11912-017-0615-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7439649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1915344932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-43d585bd467f7a9dcefb2aa65a1509efb2289acc1ed84b60d7bee0577308e3963</originalsourceid><addsrcrecordid>eNp1kc1KxTAQhYMo_j-AGym4cVOdpGnSbgSpXhUUBXUd0nZae2lTTVrBtzelKlfBVSbMd05mcgg5oHBCAeSpozSlLAQqQxA0Dvka2aZxxEPBRLo-1SwKI5nCFtlxbgnAABLYJFssEYJzSbdJlo3WohmCO210jd1UPg5WD1h_BFVvgwc0TYtBpk2BNtCmDBbjMFoMLhqLxdD0xu2RjUq3Dve_zl3yvLh8yq7D2_urm-z8Niy4hCHkURkncV5yISup07LAKmdai1jTGNLpwpJUFwXFMuG5gFLmiBBLGUGCUSqiXXI2-76OeYdeb_ygrXq1Tafth-p1o353TPOi6v5dSe7lPPUGx18Gtn8b0Q2qa1yBbasN9qNT_jf973mQefToD7rsR2v8ehPFpaSUTxSdqcL2zlmsfoahoKaI1ByR8hGpKSLFveZwdYsfxXcmHmAz4HzL1GhXnv7X9RN7RJxR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1914771142</pqid></control><display><type>article</type><title>Current Management Strategy for Penile Cancer and Future Directions</title><source>MEDLINE</source><source>SpringerLink</source><creator>Dorff, Tanya B. ; Ballas, Leslie K. ; Schuckman, Anne K.</creator><creatorcontrib>Dorff, Tanya B. ; Ballas, Leslie K. ; Schuckman, Anne K.</creatorcontrib><description>Purpose of Review
The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy.
Recent Findings
Organ preservation (surgical or incorporating radiation) and reconstructive techniques are important considerations for quality of life in penile cancer survivors. Although local recurrence may be higher with organ preservation, salvage therapy appears successful. Inguinal and pelvic node management requires multidisciplinary care, including chemotherapy; optimal use of radiation has not been fully defined. Advanced in understanding the biology of penile cancer, particularly with regard to epidermal growth factor receptor (EGFR) and HPV status, have led to clinical trials of targeted and immune therapy for patients with refractory disease.
Summary
Refinements in the management of penile cancer are occurring, though level 1 evidence remains scarce. Referral to specialized centers will facilitate successful completion of clinical trials to advance standard care in this disease.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-017-0615-4</identifier><identifier>PMID: 28664471</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cancer ; Cancer therapies ; Carcinoma, Squamous Cell - therapy ; Chemotherapy ; Circumcision ; Clinical trials ; Epidermal growth factor ; Epidermal growth factor receptors ; Genital cancers ; Genitourinary Cancers (DP Petrylak and JW Kim ; Humans ; Immune checkpoint ; Lymph Node Excision - methods ; Male ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local ; Oncology ; Pelvis ; Penile Neoplasms - therapy ; Penis ; Preservation ; Quality of Life ; Reconstructive Surgical Procedures - methods ; Salvage Therapy - methods ; Section Editors ; Topical Collection on Genitourinary Cancers</subject><ispartof>Current oncology reports, 2017-08, Vol.19 (8), p.54-54, Article 54</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Current Oncology Reports is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-43d585bd467f7a9dcefb2aa65a1509efb2289acc1ed84b60d7bee0577308e3963</citedby><cites>FETCH-LOGICAL-c470t-43d585bd467f7a9dcefb2aa65a1509efb2289acc1ed84b60d7bee0577308e3963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11912-017-0615-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11912-017-0615-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28664471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dorff, Tanya B.</creatorcontrib><creatorcontrib>Ballas, Leslie K.</creatorcontrib><creatorcontrib>Schuckman, Anne K.</creatorcontrib><title>Current Management Strategy for Penile Cancer and Future Directions</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of Review
The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy.
Recent Findings
Organ preservation (surgical or incorporating radiation) and reconstructive techniques are important considerations for quality of life in penile cancer survivors. Although local recurrence may be higher with organ preservation, salvage therapy appears successful. Inguinal and pelvic node management requires multidisciplinary care, including chemotherapy; optimal use of radiation has not been fully defined. Advanced in understanding the biology of penile cancer, particularly with regard to epidermal growth factor receptor (EGFR) and HPV status, have led to clinical trials of targeted and immune therapy for patients with refractory disease.
Summary
Refinements in the management of penile cancer are occurring, though level 1 evidence remains scarce. Referral to specialized centers will facilitate successful completion of clinical trials to advance standard care in this disease.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemotherapy</subject><subject>Circumcision</subject><subject>Clinical trials</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>Genital cancers</subject><subject>Genitourinary Cancers (DP Petrylak and JW Kim</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Lymph Node Excision - methods</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local</subject><subject>Oncology</subject><subject>Pelvis</subject><subject>Penile Neoplasms - therapy</subject><subject>Penis</subject><subject>Preservation</subject><subject>Quality of Life</subject><subject>Reconstructive Surgical Procedures - methods</subject><subject>Salvage Therapy - methods</subject><subject>Section Editors</subject><subject>Topical Collection on Genitourinary Cancers</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1KxTAQhYMo_j-AGym4cVOdpGnSbgSpXhUUBXUd0nZae2lTTVrBtzelKlfBVSbMd05mcgg5oHBCAeSpozSlLAQqQxA0Dvka2aZxxEPBRLo-1SwKI5nCFtlxbgnAABLYJFssEYJzSbdJlo3WohmCO210jd1UPg5WD1h_BFVvgwc0TYtBpk2BNtCmDBbjMFoMLhqLxdD0xu2RjUq3Dve_zl3yvLh8yq7D2_urm-z8Niy4hCHkURkncV5yISup07LAKmdai1jTGNLpwpJUFwXFMuG5gFLmiBBLGUGCUSqiXXI2-76OeYdeb_ygrXq1Tafth-p1o353TPOi6v5dSe7lPPUGx18Gtn8b0Q2qa1yBbasN9qNT_jf973mQefToD7rsR2v8ehPFpaSUTxSdqcL2zlmsfoahoKaI1ByR8hGpKSLFveZwdYsfxXcmHmAz4HzL1GhXnv7X9RN7RJxR</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Dorff, Tanya B.</creator><creator>Ballas, Leslie K.</creator><creator>Schuckman, Anne K.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170801</creationdate><title>Current Management Strategy for Penile Cancer and Future Directions</title><author>Dorff, Tanya B. ; Ballas, Leslie K. ; Schuckman, Anne K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-43d585bd467f7a9dcefb2aa65a1509efb2289acc1ed84b60d7bee0577308e3963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemotherapy</topic><topic>Circumcision</topic><topic>Clinical trials</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>Genital cancers</topic><topic>Genitourinary Cancers (DP Petrylak and JW Kim</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Lymph Node Excision - methods</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local</topic><topic>Oncology</topic><topic>Pelvis</topic><topic>Penile Neoplasms - therapy</topic><topic>Penis</topic><topic>Preservation</topic><topic>Quality of Life</topic><topic>Reconstructive Surgical Procedures - methods</topic><topic>Salvage Therapy - methods</topic><topic>Section Editors</topic><topic>Topical Collection on Genitourinary Cancers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dorff, Tanya B.</creatorcontrib><creatorcontrib>Ballas, Leslie K.</creatorcontrib><creatorcontrib>Schuckman, Anne K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dorff, Tanya B.</au><au>Ballas, Leslie K.</au><au>Schuckman, Anne K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Management Strategy for Penile Cancer and Future Directions</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>19</volume><issue>8</issue><spage>54</spage><epage>54</epage><pages>54-54</pages><artnum>54</artnum><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>Purpose of Review
The aim of this review is to evaluate the trends in multidisciplinary management of localized penile cancer and systemic therapy for advanced disease in the evolving era of targeted and immune checkpoint therapy.
Recent Findings
Organ preservation (surgical or incorporating radiation) and reconstructive techniques are important considerations for quality of life in penile cancer survivors. Although local recurrence may be higher with organ preservation, salvage therapy appears successful. Inguinal and pelvic node management requires multidisciplinary care, including chemotherapy; optimal use of radiation has not been fully defined. Advanced in understanding the biology of penile cancer, particularly with regard to epidermal growth factor receptor (EGFR) and HPV status, have led to clinical trials of targeted and immune therapy for patients with refractory disease.
Summary
Refinements in the management of penile cancer are occurring, though level 1 evidence remains scarce. Referral to specialized centers will facilitate successful completion of clinical trials to advance standard care in this disease.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28664471</pmid><doi>10.1007/s11912-017-0615-4</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2017-08, Vol.19 (8), p.54-54, Article 54 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7439649 |
| source | MEDLINE; SpringerLink |
| subjects | Cancer Cancer therapies Carcinoma, Squamous Cell - therapy Chemotherapy Circumcision Clinical trials Epidermal growth factor Epidermal growth factor receptors Genital cancers Genitourinary Cancers (DP Petrylak and JW Kim Humans Immune checkpoint Lymph Node Excision - methods Male Medicine Medicine & Public Health Neoplasm Recurrence, Local Oncology Pelvis Penile Neoplasms - therapy Penis Preservation Quality of Life Reconstructive Surgical Procedures - methods Salvage Therapy - methods Section Editors Topical Collection on Genitourinary Cancers |
| title | Current Management Strategy for Penile Cancer and Future Directions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A06%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Management%20Strategy%20for%20Penile%20Cancer%20and%20Future%20Directions&rft.jtitle=Current%20oncology%20reports&rft.au=Dorff,%20Tanya%20B.&rft.date=2017-08-01&rft.volume=19&rft.issue=8&rft.spage=54&rft.epage=54&rft.pages=54-54&rft.artnum=54&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-017-0615-4&rft_dat=%3Cproquest_pubme%3E1915344932%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1914771142&rft_id=info:pmid/28664471&rfr_iscdi=true |